Lineage Cell Stock Jumps as OpRegen Shows Additional Cases Of Retinal Tissue Restoration In Mid-Stage Study

Lineage Cell Therapeutics Inc LCTX has announced that restoration of retinal tissue was observed in two additional patients enrolled in the Phase 1/2a study of its lead product candidate, OpRegen.
OpRegen is an allogeneic retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of age-related macular degeneration (AMD) with geographic atrophy (GA) or dry (atrophic) AMD.
In addition to positive anatomical changes, all three patients' visual acuity increased above baseline levels within six months post-transplant.
In connection with these findings, Lineage has filed a Patent Cooperation Treaty (PCT) patent application which describes the restoration of the anatomy or functionality of diseased retinas.
It allowed claims of a national patent application based on the PCT application would have an estimated expiration date of at least May 24, 2041.
Overall, OpRegen has been well-tolerated with no unexpected adverse events or serious adverse events.
Evidence of durable engraftment of OpRegen RPE cells has extended to more than five years post-transplant in earliest treated patients.
Price Action: LCTX shares are up 10.6% at $2.62 during the premarket session on the last check Tuesday.